Abstract
A key component for the success of any therapeutic cytokine is the degree of immunogenicity mediated by the cytokine. There are many factors that can contribute to a cytokine being immunogenic, such as aggregation. The understanding of cytokine immunogenicity requires a thorough knowledge of the antibody testing that was performed. Some of the methods used to test for antibodies against cytokines are the enzyme-linked immunosorbent assay, radioimmune precipitation assay, electrochemiluminescence, and surface plasmon resonance platforms. To understand whether an anticytokine antibody can neutralize the biological effect of a cytokine, it is necessary to perform a bioassay. The significance of cytokine immunogenicity can only be understood in the context of antibody testing data coupled with clinical data related to effects on the patient.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1:457–462.
Hochuli E. Interferon immunogenicity: technical evaluation of interferon-α2A. J Interferon Cytokine Res 1997;17:S15–S21.
Moore WV, Leppert P. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinal Metab 1980;51:691–697.
Voller A, Bidwell D, Bartlett A. Enzyme-linked immunosorbent assay. In: Rose NR, Friedman H, eds. Manual of clinical immunology. 2nd ed. Washington, DC: American Society of Microbiology, 1980, pp. 359–371.
Knower T, Carlson J, Yarmuch DM, Yarmush ML, Granzow R. The characterization of antibody-antigen interactions by a novel sensor technology: BIACOREâ„¢. Biophys J 1991;59:170a.
Swanson SJ, Mytych D, Ferbas J. Use of biosensors to monitor the immune response. Dev Biol 2002; 109:71–78.
Swanson SJ. New technologies for the detection of antibodies to therapeutic proteins. In: Immunogenicity of Therapeutic Biological Products. Dev. Biol, vol 112. Basel: Karger; 2003, pp 127–133.
Takacs MA, Jacobs SJ, Bordens RM, Swanson SJ. Detection and characterization of antibodies to PEG-interferon alfa-2b using surface plasmon resonance. J Interferon Cytokine Res 1999; 19:781–789.
Swanson SJ, Jacobs SJ, Mytych D, Shah C, Indelicate SR, Bordens RW. Applications for the new electrochemiluminescent (ECL) and biosensor technologies. Dev Biol Stand 1999;97:135–147.
Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469–475.
Swanson SJ, Ferbas J, Mayeux P, Casadevall N. Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract 2004;96:c88–95.
Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241–3248.
Hardy L, Rogers B, Thomas D, et al. Thrombocytopenia and antigenicity assessment of thrombopoietin treated chimpanzees and rhesus monkeys. Toxicologist 1997;36:277.
Hanley JP, Haydon GH. The biology of interferon-alpha and the clinical significance of anti-interferon antibodies. Leuk Lymphoma 1998;29:257–268.
Kontsek P, Liptakova H, Kontsekova E. Immunogenicity of interferon-alpha 2 in therapy: structural and physiological aspects. Acta Virol 1999;43:63–70.
Ryff, JC. Clinical investigation of the immunogenicity of interferon-a2A. J Interferon Cytokine Res 1997;17:S29–S33.
Lindsay KL, Trepo C, Heintges T, et al. Hepatitis interventional therapy group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34:395–403.
Schellekens H, Ryff JC, van der meide PH. Assays for antibodies to human interferon-a: the need for standardisation. J Interferon Cytokine Res 1997;17:5–8.
Allegretta M, Atkins MB, Dempsey RA, et al. The development of antiinterleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2). J Clin Immunol 1986;6:481–490.
Scharenberg JG, Stam AG, von Blomberg BM, et al. The development of antiinterleukin-2(IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur J Cancer 1994;30:1804–1809.
Ullenhag G, Bird C, Ragnhammar P, et al. Incidence of GM-CSF antibodies in cancer patients receiving GM-CSF for immunostimulation. Clinical Immunology 2001; 99:65–74.
Larocca AP, Leung SC, Marcus SG, Colby CB, Borden EC. Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser. J Interferon Res 1989;9:S51–S60.
Perini P, Facchinetti A, Bulian P, et al. Interferon-beta (INF-beta) antibodies in interferon-betala-and interferon-betalb-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001;12:56–61.
Abdul-Ahad AK, Galazka AR, Revel M, Biffoni M, Borden EC. Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta la from mammalian cells. Cytokines Cell Mol Ther 1997;3:27–32.
Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Ann Neurol 2000;48:706–712.
Koren E, Zuckerman LA, Mire-Sluis AR. Immune response to therapeutic proteins in humans—clinical significance, assessment and predicition. Curr Pharm Biotechnol 2002;3:349–360.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Swanson, S. (2007). Evaluation of Antibodies in Clinical Trials of Cytokines. In: House, R.V., Descotes, J. (eds) Cytokines in Human Health. Methods in Pharmacology and Toxicology. Humana Press. https://doi.org/10.1007/978-1-59745-350-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-59745-350-9_13
Publisher Name: Humana Press
Print ISBN: 978-1-58829-467-8
Online ISBN: 978-1-59745-350-9
eBook Packages: Springer Protocols